Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03955783
Title Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michael Byrne
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.